Minutes
Meeting of Council on Sponsored Activities
September 28, 2010
Location: 204 Parkhurst Conference Room
2:00 – 3:30 pm

Call to Order: The meeting was called to order by Chair Martin Wybourne at 2:05 p.m. A quorum was present.

Members Present: Martin Wybourne, Elsa Garmire, Todd Heatherton, Leslie Henderson, Paul Guyre, David Kotz, Robert Donin, Tillman Gerngross and Jon Kull

Members Absent: Stephen Kadish, Robert Hansen

Guests: Elizabeth Bankert

Approval of the July 13, 2010 Meeting Minutes, Minutes approved with correction of typo on second page.

Updates:

a. Replacement for Electronic Research Administration (ERA) Currently OSP and the CPHS office use the ERA program, COEUS. COEUS is being phased out by January 2013. An update was provided on the review process for replacement systems: four full-day vendor demonstrations had good attendance. Jill Mortali reported that Click Commerce seemed to be the front runner and that the two final front runners may be reviewed in further detail OSP and CPHS are in the process of obtaining evaluations from other institutions using the systems. The CSA will be invited to a summary presentation in late October.

b. DHHS Proposed Rule on Investigator Conflicts of Interest – There have been no updates to the proposed rule changes.

Discussion of Conflict of Interest Committee Operations – Continued discussion related to how the new on-line COI disclosure system may impact the administrative review process. Dedicated COI staff support would be very helpful. This topic hasn’t been broached with Carol Folt or Steve Kadish, but in the new NIH rules and the new on-line system, Dartmouth may need to have an individual devoted 100% to research COI. The revised Conflict of Interest Policy includes the appointment of a COI chair. It may be useful to have a brief summary of the role and responsibilities of the Chair prior to appointment.
We are awaiting approval of the Human Subject Conflict of Interest Policy by Dartmouth-Hitchcock.

**Commercial vs Internal IRB reviews – general discussion**
Over the past several years there has been a national discussion related to the use of Commercial IRBs vs. local IRB review. The discussion initiated from the concern that multi-center studies require multiple local IRBs reviewing the same protocol leading to a higher administrative burden and extended timeframe. Pharmaceutical companies are considering using institutions that use a commercial IRB. Liz Bankert has been asked to obtain information related to this topic and to submit to Martin Wybourne and the CSA for consideration.

**Other Business**
Concern expressed about whether the new financial center models may not be in the best interest of the labs. How can the researchers be efficient with the new procedures? Can there be more communication between administration and researchers, regarding their needs?

**Adjournment** – The meeting adjourned at 3:35 p.m.